Vertex Urged To Target Major M&A After Another Rare Disease Failure
Slip-Up Good News For Arrowhead
After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.
You may also be interested in...
With more data reported at ASH, Vertex and CRISPR Therapeutics added heft to the notion that functional cures are on the horizon for the inherited blood disorders sickle cell disease and beta-thalassemia. Attention is now turning to Bluebird’s marketing strategy after a filing delay.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.